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Abstract: Colorectal cancer is considered a disease of the elderly population. Since the number 
of geriatric patients continues to rise, monoclonal antibody therapy is the most promising 
therapy in the recent research. Presently, the monoclonal antibodies most frequently used in the 
treatment of colorectal tumors are bevacizumab, cetuximab, panitumumab, and ramucirumab. 
Bevacizumab is a monoclonal antibody that acts on VEGF. Cetuximab and panitumumab act 
on EGFR. Ramucirumab binds directly to the ligand-binding pocket of VEGFR-2 to block 
the binding of VEGF-A, VEGF-C, and VEGF-D. These monoclonal antibodies, alone or in 
association with radiotherapy or chemotherapy, are presenting good results and are increasing 
patient survival, despite the side effects. Due to the limited number of molecules available, 
several studies are trying to develop new monoclonal antibodies for the treatment of colorec-
tal tumors. Among those being studied, some recent molecules are in phase I and/or II trials 
and are yielding advantageous results, such as anti-DR5, anti-Fn14, anti-IGF-1R, anti-EGFR, 
anti-NRP1, and anti-A33 antibodies. This has been successful in reducing side effects and in 
treating nonresponsive patients.
Keywords: monoclonal antibodies, colorectal tumor, bevacizumab, cetuximab, panitumumab, 
ramucirumab
Colorectal tumor
Colorectal cancer is considered a heterogeneous disease, both in relation to the 
pathogenesis and the clinical signals.1 The incidence of colorectal cancer is higher 
in people between 60 and 70 years of age. Twenty percent of cases occur before the 
age of 50. Colorectal cancer is more prevalent in the US, Canada, Australia, New 
Zealand, Denmark, Sweden, and other developed countries. The incidence is 30 
times lower in India, South America, and Africa. In Japan, the incidence is increas-
ing gradually, reaching similar rates in the UK, presumably as a result of changes in 
lifestyle and diet.2–7
The discovery of sequences of genes associated with adenoma–carcinoma has 
contributed to understanding the genetic and epigenetic alterations that drive the for-
mation of colorectal cancer. Among the genetic alterations associated with colorectal 
cancer, abnormal activation of the Wnt/β-catenin signaling pathway has an important 
role, because Wnt pathway is crucial in cell proliferation and migration.8
Somatic mutations may play an important role as prognostic or predictive mark-
ers for the development of specific therapies in colorectal cancer. These mutations 
involve genes such as KRAS, BRAF, PIK3CA, AKT1, PTEN, NRAS, and TGFBR2.9–15 
Therefore, epigenetic and gene silencing events may increase the progression of 
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colorectal cancer.16 This finding opens new possibilities 
for high-precision laboratory tests such as the identification 
of molecular markers in screening tests for noninvasive 
colorectal adenocarcinoma.17
Supporting treatment with 
monoclonal antibodies
Approved monoclonal antibodies 
for therapy
Several monoclonal antibodies for different therapeutic 
targets have already been approved for use in patients with 
tumors. For example, cetuximab and panitumumab are mono-
clonal antibodies directed at the EGFR.4,18,19 Bevacizumab is 
targeted to the VEGF.20,21 Ramucirumab inhibits VEGF and 
VEGF receptor.22,23 Moreover, for the CD20 target, rituximab, 
ofatumumab, tositumomab, and ibritumomab tiuxetan24–26 are 
used. The antibodies trastuzumab, pertuzumab, trastuzumab, 
and emtansine are directed HER2/neu.27–33 The monoclonal 
antibody that targets the CD33 molecule is gemtuzumab 
ozogamicin.31,34 Alemtuzumab binds to CD52,35,36 while 
brentuximab vedotin is directed at the CD30 molecule.37 
Ipilimumab binds to the CTLA4 molecule, among others.38,39 
Still under development are monoclonal antibodies directed 
at new or older potential targets, but are not yet approved for 
use in patients.18,25,40–43
Approved monoclonal antibodies for 
colorectal tumors
At present, among biological molecules, a few antibodies 
have their use approved for the treatment of colorectal tumors 
(Table 1). The four approved monoclonal antibodies showing 
favorable results for use in the treatment of colorectal cancer 
are bevacizumab, cetuximab, panitumumab, and ramuci-
rumab, which are detailed in the following section.42,44–46
Cetuximab
Cetuximab is a monoclonal antibody, IgG1 kappa human/
murine chimeric, with constant regions and murine variable 
regions. It recognizes the extracellular domain of the EGFR 
and therefore can block the tumor growth.47
After binding to the extracellular domain of EGFR, this 
antibody prevents the signaling and ligand-induced dimeriza-
tion of the receptor. In this way, it blocks the signals of cell 
growth and tumor survival. Cetuximab may have the function 
of mediating antibody-dependent cellular cytotoxicity 
(ADCC). This monoclonal antibody only achieves dynamic 
equilibrium after the third week of infusion.48–56 In addition, 
this biological molecule was approved by the US Food and 
Drug Administration (FDA) for patients with metastatic 
colorectal cancer (mCRC), especially for patients who do not 
tolerate irinotecan (a chemotherapeutic drug), and was also 
associated with irinotecan for patients who do not tolerate 
oxaliplatin, irinotecan, and 5-fluorouracil (5-FU).57,58
Some patients present an anaphylactic reaction. A study 
has shown that there is a higher incidence of anaphylaxis 
in people who have a history of allergies to red meat and 
tick bites.59 Cutaneous reactions are considered severe with 
cetuximab. Cytokine release syndrome occurs usually 1 hour 
after the infusion. This reaction is usually more severe after 
the first infusion.60 Electrolyte disturbances and neutropenia 
events may be related to the associated chemotherapy using 
platinum-based compounds. Eye infections such as ulcerative 
dermatitis can also occur.61
Cetuximab has demonstrated benefits only in a small 
subset of metastatic patients (KRAS wild-type patients 
and patients with limited metastatic disease). Alterna-
tive strategies that demonstrate promising results for 
the treatment of rectal cancer during stage II/III include 
short-course radiotherapy with adjuvant chemotherapy and 
neoadjuvant FOLFOX (folinic acid, 5-FU, and oxaliplatin)– 
bevacizumab without radiotherapy.62
Panitumumab
Panitumumab is a humanized IgG2 kappa antibody with com-
plementary determining regions (CDRs) of murine origin. It is 
directed against the EGFR. When compared with cetuximab, 
Table 1 Approved antibodies for the treatment of colorectal tumor
Monoclonal antibody Therapeutic target Mechanism of action Indication approved (FDA)
Bevacizumab 
(humanized igG1)
veGF inhibition of veGF Colorectal cancer – palliative treatment
Cetuximab (humanized/
murine chimeric igG1)
eGFR (erbB1) inhibition of eGFR; ADCC Colorectal cancer – palliative treatment
Panitumumab eGFR inhibition of eGFR Metastatic colorectal carcinoma – with 
eGFR expression
Ramucirumab veGF receptor-2 Blockage of veGF-A, veGF-C, 
and binding of veGF-D
mCRC – in combination with FOLFiRi 
(irinotecan, folinic acid, and 5-fluorouracil)
Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; FDA, US Food and Drug Administration; mCRC, metastatic colorectal cancer.
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it is a murine antibody with reduced portions. However, 
panitumumab is not able to mediate ADCC.56,63 The mechanism 
of action of panitumumab is due to its binding to EGFR and 
blocking of this receptor. It inhibits the autophosphorylation 
of the receptor induced by the ligands of EGFR that internal-
izes their functions. In conclusion, the monoclonal ligation 
inhibits cell growth, induces cell apoptosis, and inhibits the 
production of interleukin-8 and VEGF.64
This monoclonal antibody is approved for use in adult 
patients. Patients with mCRC expressing EGFR in treatment 
with panitumumab have presented a better response.65 The 
most frequently reported adverse reactions, in monotherapy 
or in conjunction with chemotherapy, were skin reactions, 
gastrointestinal disorders, nutrition and metabolic disorders, 
anorexia, chills, fever, and dyspnea.66
Bevacizumab
Bevacizumab is a recombinant humanized monoclonal IgG1 
antibody that binds to VEGF.21,67,68 Bevacizumab has an 
important role in the treatment of colon tumors, but has been 
used in the treatment of other tumors with favorable results 
since its role in blocking angiogenesis is of fundamental 
importance in tumor biology.69
Bevacizumab, when used in association with chemo-
therapy, effectively reduces the progression of tumors in the 
lungs, colorectal tumors, and breast cancer. The proposed 
mechanism of action of bevacizumab is related to prevent-
ing the interaction of VEGF with VEGFR-1 (Flt-1) and 
VEGFR-2 (KDR/Flk-1). These receptors are proteins located 
in the cytoplasmic domain and are connected to the extracel-
lular matrix. VEGF is on top of the cytoplasmic membrane. 
Bevacizumab binds to VEGF and prevents the proliferation 
of endothelial cells and formation of blood vessels, as well 
as decreases the blood supply and reduces tumor interstitial 
pressure. Thus, the ability of chemotherapy to reach the tumor 
is increased by the combinatorial treatment.20,70–73
In general, in patients with metastatic carcinoma of the 
colon or rectum, this antibody is used in combination with a 
fluoropyrimidine chemotherapeutic drug.74,75 Bevacizumab is a 
monoclonal antibody with remarkable antiangiogenic capacity, 
but is associated with serious cases of gastrointestinal perfora-
tion and fistulas, bleeding, bleeding associated with the tumor, 
and hypertension. Injured or postsurgery patients should not 
make use of bevacizumab, since it can reduce healing, causing 
a wound dehiscence and even perforation or abscesses.76
Ramucirumab
In 2015, ramucirumab was approved by the FDA for the treat-
ment of patients with colorectal cancer.77 It is a fully humanized 
IgG1 monoclonal antibody that targets the extracellular domain 
of VEGF and VEGFR-2. The binding of the monoclonal anti-
body inhibits the activation and signaling of these molecules/
receptors.78 It is also believed that VEGF and VEGFR-2 mediated 
angiogenesis in colorectal cancer.22 Ramucirumab, in combina-
tion with FOLFIRI (irinotecan, folinic acid, and 5-FU), is indi-
cated for the treatment of patients with mCRC with the disease 
in progression or after therapy with bevacizumab, oxaliplatin, 
and fluoropyrimidine. The usual dose is 8 mg/kg ramucirumab 
plus FOLFIRI every 2 weeks.79 Ramucirumab presents the risk 
of hemorrhage and gastrointestinal hemorrhage, including severe 
and sometimes fatal hemorrhagic events.23,77–81
Monoclonal antibodies in clinical trials 
from 2012 to 2016
Bevacizumab is considered a milestone in the treatment of 
colorectal cancer and is helpful when used in combination 
with chemotherapy. On the other hand, the anti-EGFR anti-
bodies, also relevant in practice, have limited application 
for cases of mutations of K-ras gene. Since the currently 
approved monoclonal antibodies act due to the inhibition of 
VEGF or EGFR, they did not present clinical efficacy in all 
patients with colorectal tumors. Due to this, the new anti-
bodies under development are a therapeutic promise. These 
monoclonal antibodies present a different mechanism of 
action and the possibility of reduced side effects. However, 
detailed clinical trials are under way to verify if these new 
molecules are more effective than the already approved 
antibodies. Also, these trials are necessary to determine their 
drawbacks and adverse effects. The newest developments 
in monoclonal antibodies for immunotherapy are detailed 
in Table 2 and in the following section.
Fibroblast growth factor-inducible 14 (Fn14) 
molecules
RG7212 is a monoclonal antibody in phase I immuno-
therapy study. It is a first-in-class, fully humanized IgG1 
kappa monoclonal antibody. RG7212 blocks TNF (tumour 
necrosis factor)-like weak inducer of apoptosis (TWEAK) 
by binding to the Fn14 receptor. TWEAK and Fn14 are 
a ligand–receptor pair frequently overexpressed in solid 
tumors. TWEAK induces cell proliferation, survival, and 
NF-κB signaling. RG7212 had good tolerability and favor-
able pharmacokinetics in combination therapies in patients 
with Fn14-positive tumors.82
Anti-DR5 antibodies
Tigatuzumab is a humanized monoclonal IgG1 agonist of 
human DR5, also known as member 10b of the TNF receptor 
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superfamily (TNFRSF10B) or TRAIL-R2. DR5 is a protein 
overexpressed in many kinds of tumors. It is under clinical 
trial in patients with mCRC.83
Drozitumab is a fully humanized IgG1 that also binds 
with DR5. It is under phase I study combined with FOLFOX6 
and bevacizumab. Patients with mCRC presented a partial 
response in this trial.84
Anti-eGFR antibodies
Nimotuzumab is a humanized monoclonal IgG1 antibody 
that binds to the EGFR with intermediate affinity.85,86 It has 
presented good efficacy in phase II trials of radiotherapy 
and in combination with capecitabine in advanced rectal 
cancer.87
Anti-iGF-1R antibodies
Robatumumab is an IGF-1R monoclonal antibody under 
phase II study in patients with advanced colorectal cancer.88 
It acts by inhibiting tumor-derived VEGF and, indirectly, 
angiogenesis.89 However, few patients appeared to benefit 
from treatment with robatumumab.88
Dalotuzumab (MK-0646) is a recombinant humanized 
IgG1 mAb, also against the IGF-1R. It is under a phase I 
study in combination with cetuximab and irinotecan and 
is given to patients with advanced colorectal cancer.90 
Robatumumab acts by reducing IGF-1- and IGF-2-mediated 
tumor cell proliferation, IGF-1R autophosphorylation, and 
Akt phosphorylation.
Also, figitumumab is a monoclonal antibody under a phase II 
clinical trial for patients with refractory mCRC. It is a humanized 
IgG2 isotype that binds and reduces the activation of IGF-1R. 
However, no partial or complete responses occurred in this trial, 
and further study of figitumumab was not supported.91
Anti-A33 antibodies
KRN330 is a fully humanized monoclonal antibody 
directed against A33. A33 is a 43 kDa transmembrane 
glycoprotein of the immunoglobulin superfamily that is 
highly expressed in intestinal epithelium and expressed in 
95% of colorectal cancers. This monoclonal antibody seems 
to stimulate cytotoxic T-lymphocyte (CTL) response against 
A33-positive colorectal cancers. In the phase II study, the 
prespecified objective response rate to the treatment with 
KRN330 and irinotecan was not met.92
I-huA33, another anti-33 monoclonal antibody, combined 
with capecitabine, is under a phase I trial for mCRC. In this trial, 
I-huA33 is achieving specific targeting to colorectal cancer 
metastases and is safely combined with chemotherapy.93
Table 2 New monoclonal antibodies under clinical trials for the treatment of colorectal tumor
Monoclonal antibody Therapeutic 
target
Mechanism of action Trials
RG7212 (fully humanized 
igG1 kappa)
Fn14 inhibits TweAK; reduces proliferation, survival, 
and NF-κB signaling
Phase i trial for solid tumors
Tigatuzumab (CS-1008; 
humanized igG1)
DR5 (TNFRSF10B 
or TRAiL-R2)
Agonist of DR5, apoptosis induction, and 
cytotoxic activity
Phase ii trial for mCRC
Nimotuzumab (humanized igG1) extracellular 
domain of eGFR
inhibits eGFR Phase ii trial for local advanced 
colorectal tumor
Figitumumab (fully humanized 
igG2)
iGF-1R Reduces the activation of iGF-1R Phase ii clinical trial for refractory 
mCRC
Robatumumab (R-1507, 19D12, 
or SCH 717454; fully humanized 
igG1 kappa isotype)
iGF-1R Antagonist of iGF-1R, inhibits veGF and 
angiogenesis
Phase ii study for advanced  
colorectal cancer
KRN330 (fully humanized ig) A33 glycoprotein Stimulates CTL response against A33-positive 
colorectal cancer
Phase i/ii study, in combination with 
irinotecan for mCRC
i-huA33 (fully humanized igG1) A33 glycoprotein Stimulates CTL response against A33-positive 
colorectal cancer
Phase i trial, in combination with 
capecitabine for mCRC
MNRP1685A (fully humanized 
igG1 isotype)
NRP1 Targets the veGF binding domain of NRP1; 
reduces angiogenesis, cell survival, migration, 
and invasion
Phase i trial, in combination with  
anti-veGF therapies to advanced 
tumors
Dalotuzumab (MK-0646; fully 
humanized igG1 isotype)
iGF-1R Antagonist of iGF-1R; inhibits iGF-1- and  
iGF-2-mediated tumor cell proliferation, iGF-1R 
autophosphorylation and Akt phosphorylation
Phase i study, in combination with 
cetuximab and irinotecan  
for advanced colorectal cancer
Drozitumab (anti-TRAiL, 
PRO-95780, RG7425; fully 
humanized igG1)
DR5 Agonist of DR5, apoptosis induction, cytotoxic 
activity
Phase i study, in combination 
with first-line mFOLFOX6 plus 
bevacizumab for mCRC
Abbreviations: 5-FU, 5-fluorouracil; CTL, cytotoxic T-lymphocyte; Fn14, fibroblast growth factor-inducible 14; mCRC, metastatic colorectal cancer; mFOLOFOX, 
oxaliplatin, folinic acid, 5-FU in combination with either panitumumab or cetuximab; TweAK, tumour necrosis factor-like weak inducer of apoptosis.
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Anti-NRP1 antibodies
MNRP1685A is a fully humanized IgG1 directed against 
NRP1. NRP1 is overexpressed by certain tumor cells. 
This monoclonal antibody has potential antineoplastic 
activities by preventing coupling of NRP1 to VEGFR-2 
and potentially inhibiting VEGF-mediated signaling and 
angiogenesis. MNRP1685A, in combination with anti-
VEGF therapies, may present an enhanced antiangiogenic 
effect and is under phase I trials in patients with advanced 
solid tumors.94
Future perspectives
Presently, new strategic trials are being developed due to 
the elevated cost of new agents and reduced number of 
molecules available. Furthermore, molecular-targeted agents 
such as antiangiogenic agents (bevacizumab, aflibercept, and 
regorafenib) and anti-EGFR agents (cetuximab and panitu-
mumab) have been associated with chemotherapeutic drugs 
(fluoropyrimidine, oxaliplatin, and irinotecan), as described 
in the following section.
The combination of monoclonal antibodies anti-VEGF 
or anti-EGFR with chemotherapy has shown good clinical 
activity in cases of metastatic colorectal tumors. However, 
the use of both molecules combined with chemotherapy 
presented several adverse outcomes. Clinical trials are under 
development to test the effects of bevacizumab plus erlotinib, 
as well as bevacizumab plus tegafur/uracil and leucovorin, 
as a first-line treatment for patients with mCRC.95 Also, 
STRATEGIC-1, a phase III trial, is in progress with the purpose 
of creating global information on the treatment sequence for 
patients with unresectable RAS wild-type colorectal cancer. In 
this trial, FOLFIRI + cetuximab + oxaliplatin + bevacizumab 
is compared to OPTIMOX + bevacizumab + irinotecan.96
Panitumumab or bevacizumab with FOLFIRI (SPIRITT) 
is also under evaluation as a second-line treatment. This 
combination presented similar efficacy as oxaliplatin-
based chemotherapy with bevacizumab, with expected 
toxicities.97
Necitumumab plus modified FOLFOX6 (oxaliplatin, 
folinic acid, 5-FU in combination with either panitumumab 
or cetuximab) was recommended as the first-line treat-
ment for patients with RAS mutation and as first-line treat-
ment for locally advanced cancers or mCRC and is also in 
evaluation.98
Conversely, dalotuzumab plus irinotecan and cetuximab 
did not improve survival outcome in KRAS wild-type 
mCRC.99 Meta-analysis studies showed that anti-EGFR 
monoclonal antibodies alone or in combination with others 
(FOLFIRI ± cetuximab; FOLFOX4 ± cetuximab; oxaliplatin or 
irinotecan-based chemotherapy, bevacizumab ± panitumumab; 
bevacizumab, capecitabine, oxaliplatin ± cetuximab, and iri-
notecan ± cetuximab) did not present efficacy in patients with 
mCRC containing KRAS mutations.100–102
Conclusion
This review concludes that the repertoire of approved mono-
clonal antibodies used to treat patients with colorectal tumors, 
especially in cases of malignant and metastatic tumors, is 
very limited. Nowadays, these biological molecules belong 
to only two classes of monoclonal antibodies: specific binders 
of VEGF or of EGFR. Despite the occurrence of side effects 
and higher costs of the treatment, researchers are constantly 
looking for new monoclonal antibodies for the treatment 
of colorectal tumors. New classes of molecules are under 
clinical trials with promising results.
A further possibility for identifying tumors is the use 
of biomarkers to optimize therapeutic efficacy and reduce 
toxicity. One of the current trends is the individualization 
of systemic treatment, which has become possible due to 
molecular biology tools and statistical analysis based on 
biologically plausible principles.
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